PPARα激动剂降血脂作用的研究进展

被引：22

作者：

胡越

许军

刘燕华

王增涛

黄黎敏

方加龙

王晨

机构：

[1] 江西中医药大学药物化学教研室

来源：

中国药科大学学报 | 2016年 / 47卷 / 01期

关键词：

过氧化物酶体增殖物激活受体α; 激动剂; 降血脂; 进展;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

PPARα是PPARs家族一个重要的亚型,PPARs是一组核激素受体,属于Ⅱ型核受体超家族。PPARα激动剂临床上用于治疗高脂血症。PPARα激动剂主要包括天然型和合成型两大类。其中,合成型PPARα激动剂从结构上可分为苯基并杂环类、酰脲类、酰胺类、苯基噁唑(噻唑)类等。目前已有不少PPARα激动剂被批准用于临床或处于临床研究阶段。本文从PPARα的结构特点及生理功能出发,根据其结构分类,对上述各类PPARα激动剂的研究进展进行了综述。

引用

页码：118 / 124

页数：7

共 28 条

[1]

PPARs激动剂在心脑血管疾病中的研究进展 [J].

曾正英 ;

廖高鸿 ;

吕雅斐 ;

陈国良 .

中国药物化学杂志, 2014, 24 (02) :147-156

[2]

Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome [J].

Khera, Amit V. ;

Millar, John S. ;

Ruotolo, Giacomo ;

Wang, Ming-Dauh ;

Rader, Daniel J. .

EUROPEAN HEART JOURNAL, 2015, 36 (43) :3020-3022

[3]

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.[J].Zhong-Min Liu;Miao Hu;Paul Chan;Brian Tomlinson.Expert Opinion on Investigational Drugs.2015, 5

[4]

The Dipeptide H-Trp-Arg-OH (WR) Is a PPARα Agonist and Reduces Hepatic Lipid Accumulation in Lipid-Loaded H4IIE Cells [J].

Jia, Yaoyao ;

Kim, Jong-Ho ;

Nam, Bora ;

Kim, Jiyoung ;

Lee, Ji Hae ;

Kim, Kyung Ok ;

Hwang, Kwang Yeon ;

Lee, Sung-Joon .

APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2015, 175 (02) :1211-1220

[5]

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease [J].

Pawlak, Michal ;

Lefebvre, Philippe ;

Staels, Bart .

JOURNAL OF HEPATOLOGY, 2015, 62 (03) :720-733

[6]

The role of albumin and PPAR-α in differentiation-dependent change of fatty acid profile during differentiation of mesenchymal stem cells to hepatocyte-like cells [J].

Esmaeli, Shahnaz ;

Allameh, Abdolamir ;

Soleimani, Masoud ;

Rahbarizadeh, Fatemeh ;

Frouzandeh-Moghadam, Mehdi .

CELL BIOCHEMISTRY AND FUNCTION, 2014, 32 (05) :410-419

[7]

Molecular determinants for improved activity at PPARα: Structure–activity relationship of pirinixic acid derivatives; docking study and site-directed mutagenesis of PPARα.[J].Christina Lamers;Michaela Dittrich;Ramona Steri;Ewgenij Proschak;Manfred Schubert-Zsilavecz.Bioorganic & Medicinal Chemistry Letters.2014, 16

[8]

trans -Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-α.[J].Chunyan Wu;Yaoyao Jia;Ji Hae Lee;Hee-jin Jun;Hae-Seung Lee;Kwang-Yeon Hwang;Sung-Joon Lee.Bioorganic & Medicinal Chemistry Letters.2014,

[9]

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease [J].

Sahebkar, Amirhossein ;

Chew, Gerard T. ;

Watts, Gerald F. .

EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) :493-503

[10]

Integrated Physiology and Systems Biology of PPARα.[J].Sander Kersten.Molecular Metabolism.2014,

← 1 2 3 →